1-[(Ethylamino)methyl]cyclobutan-1-ol | 1502030-73-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[(Ethylamino)methyl]cyclobutan-1-ol
• 英文别名: 1-(ethylaminomethyl)cyclobutan-1-ol
• CAS: 1502030-73-0
• 化学式: C₇H₁₅NO
• 分子量: 129.2
• InChiKey: GIRVJYDMKJVHSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS<br/>[FR] COMPOSÉS POLYHÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE METTL3
  申请人：STORM THERAPEUTICS LTD

  公开号：WO2021111124A1

  公开（公告）日：2021-06-10

  The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X-Y-Z (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.

  本发明涉及具有以下式（I）的化合物，其作为METTL3（N6-腺苷-甲基转移酶70kDa亚基）酶活性的抑制剂：X-Y-Z（I），其中X、Y和Z如本文所定义。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗增生性疾病（如癌症）、自身免疫疾病以及METTL3活性相关的其他疾病或病况中的用途。
• IRAK degraders and uses thereof
  申请人：Kymera Therapeutics, Inc.

  公开号：US11117889B1

  公开（公告）日：2021-09-14

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用方法。
• Heterocyclic compound serving as FGFR4 inhibitor
  申请人：Hangzhou Innogate Pharma Co., Ltd.

  公开号：US11352353B2

  公开（公告）日：2022-06-07

  A heterocyclic compound which is an inhibitor of FGFR4 (fibroblast growth factor receptor 4) is described. Specifically, a compound represented by the following formula (I), including an isomer (enantiomer or diastereomer) which may be present, or a pharmaceutically acceptable salt thereof, prodrugs, deuterated derivatives, hydrates, solvates, are described. The definition of each group in the formula (I) is as described in the specification. The compounds have FGFR4 inhibitory activity and can be used for the prevention or treatment of diseases associated with FGFR4 activity or expression, and can also be used in combination with other drugs for the treatment of various related diseases, as described.

  一种杂环化合物，该化合物为FGFR4的抑制剂。具体地，所述化合物如以下的式(I)所示，包括其存在的异构体(包括对映体或非对映体)，或者所述化合物的药学上可接受的盐，前药，氘代衍生物，水合物，溶剂合物。其定义如权利要求所述。所述化合物具有FGFR4抑制活性，可以用于预防或治疗与FGFR4活性或表达相关的疾病，同时也可用于与其它药物合用，用于治疗多种相关疾病。
• HETEROCYCLIC COMPOUND SERVING AS FGFR4 INHIBITOR
  申请人：Hangzhou Innogate Pharma Co., Ltd.

  公开号：US20200199120A1

  公开（公告）日：2020-06-25

  A heterocyclic compound which is an inhibitor of FGFR4 (fibroblast growth factor receptor 4) is described. Specifically, a compound represented by the following formula (I), including an isomer (enantiomer or diastereomer) which may be present, or a pharmaceutically acceptable salt thereof, prodrugs, deuterated derivatives, hydrates, solvates, are described. The definition of each group in the formula (I) is as described in the specification. The compounds have FGFR4 inhibitory activity and can be used for the prevention or treatment of diseases associated with FGFR4 activity or expression, and can also be used in combination with other drugs for the treatment of various related diseases, as described.